Chemistry:Bezisterim
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | NE3107; HE3286 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H30O3 |
| Molar mass | 330.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bezisterim (NE3107) is an analog of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the blood-brain barrier and does not activate any neurotransmitter receptors.[1] It has been tested as a treatment for Alzheimer’s disease[2][3][4][5] and traumatic brain injury.[6]
References
- ↑ Reading, Chris L; Ahlem, Clarence N; Parameswaran, Narayanan (December 2021). "Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial". Alzheimer's & Dementia 17 (S9). doi:10.1002/alz.057438.
- ↑ Stoiljkovic, Milan; Horvath, Tamas L.; Hajós, Mihály (July 2021). "Therapy for Alzheimer's disease: Missing targets and functional markers?". Ageing Research Reviews 68: 101318. doi:10.1016/j.arr.2021.101318. PMID 33711510.
- ↑ Balzano, Tiziano; Esteban-García, Noelia; Blesa, Javier (2 January 2023). "Neuroinflammation, immune response and α-synuclein pathology: how animal models are helping us to connect dots". Expert Opinion on Drug Discovery 18 (1): 13–23. doi:10.1080/17460441.2023.2160440. PMID 36538833.
- ↑ Liu, Ping; Wang, Yunyun; Sun, Yan; Peng, Guoping (April 2022). "Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease". Clinical Interventions in Aging 17: 665–674. doi:10.2147/CIA.S357558. PMID 35520949.
- ↑ Xi, Yilong; Chen, Yun; Jin, Yi; Han, Guochen; Song, Mingjie; Song, Tingting; Shi, Yang; Tao, Ling et al. (May 2022). "Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy". Journal of Controlled Release 345: 38–61. doi:10.1016/j.jconrel.2022.02.034. PMID 35257810.
- ↑ "U.S. Clinical Trial: Neurological Associates of West Los Angeles Listed a New Clinical Trial to Study Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury." Contify Life Science News, 1 Aug. 2023, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A759542006/HRCA?u=anon~bb46c85&sid=sitemap&xid=0c315c7e. Accessed 14 Dec. 2023.
 |  |
